Russian manufacturers have developed analogues of the diabetes and obesity drug Ozempic (semaglutide). To date, the country is supplied with its own drugs, said Alla Samoilova, head of Roszdravnadzor.
“When the supplier of the drug for the treatment of type 2 diabetes and obesity, the well-known Ozempic, discontinued its supply, several Russian manufacturers began producing analogues. Today, the domestic market is already fully supplied with Russian-made diabetes and weight loss drugs,” Samoilova stated during a meeting with Prime Minister Mikhail Mishustin.
Samoilova noted that medicines are subject to mandatory rigorous control, with 13 laboratories established across all federal districts.
Novo Nordisk, a Danish pharmaceutical firm that manufactures Ozempic, halted its supply of the drug to Russia in March 2023. In response, local manufacturers rolled out drug analogues: Geropharm’s Semavic, Promomed’s Quincenta, and PSK Pharma’s Insudive. By 2024, Russian pharmaceutical companies had nearly 100% of the domestic semaglutide market, as sales of analogues increased more than threefold compared to the previous year, reaching 8.8 billion rubles. Additionally, government procurement contributed another 1.7 billion rubles to manufacturers’ revenue.
In August 2025, the Supreme Court of the Russian Federation allowed the production of Ozempic versions without the consent of the patent owner.
